Kim S-H, Kim D-W. Comment on “Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors”. Haematologica [Internet]. 2015Mar.4 [cited 2026Nov.14];100(3):e120-e121. Available from: https://haematologica.org/article/view/7320